Fortrea Holdings Inc. is a biotechnology company focused on developing and commercializing innovative therapeutics for unmet medical needs, particularly in the fields of oncology and rare diseases. The company leverages advanced scientific research and technology to create transformative treatment options that aim to improve patient outcomes and quality of life. Through a combination of cutting-edge drug development and strategic partnerships, Fortrea Holdings is dedicated to bringing new therapies to market while adhering to rigorous safety and efficacy standards in the healthcare industry. Read More
DURHAM, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced that chief executive officer, Anshul Thakral, chief financial officer, Jill McConnell, and senior vice president of investor relations, Tracy Krumme, will participate in the following conferences in December:
A number of stocks jumped in the afternoon session after reports revealed the Trump administration considered extending the Affordable Care Act (ACA) subsidies. These subsidies, which are government financial aids to help people pay for health insurance, are crucial for insurers as they maintain a stable customer base. An extension would ensure continued revenue for companies with significant exposure to the ACA marketplace. The news prompted a strong positive reaction from investors, with Centene (CNC) shares jumping as much as 8%, Molina Healthcare (MOH) rising over 3%, and Oscar Health (OSCR) soaring 18%. The potential for a two-year extension reduces regulatory uncertainty for the sector, which investors view as a significant positive for the industry's outlook.
DURHAM, N.C., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it has completed its debt tender offer (the “Tender Offer”) described in the Offer to Purchase dated October 20, 2025 by purchasing $75,743,000 in aggregate of the Company’s outstanding 7.500% Senior Secured Notes due 2030 (CUSIP No. 34965K AA5 (Rule 144A); U31685 AA5 (Reg S)) (each, a “Note” and collectively, the “Notes”). The Tender Offer to repurchase of a portion of the Notes satisfied a requirement relating to the Company’s divestiture of its Fortrea Patient Access and Endpoint Clinical businesses completed in June 2024. Fortrea’s purchase of the tendered Notes on November 21, 2025, reduced the principal outstanding on the Notes from $570,000,000 to $494,257,000.
A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to markets amid concerns over high valuations, particularly in AI-related stocks.
DURHAM, N.C., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced the appointment of Agnieszka (Aggie) M. Gallagher as general counsel. Gallagher is responsible for the Company’s legal strategy and operations, serving as corporate secretary, chief compliance officer and as a member of Fortrea’s leadership team. She succeeds J. Stillman Hanson, who is leaving the Company after a planned transition period.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand.
The result? Over the past six months, the industry’s 11.6% return has trailed the S&P 500 by 4.7 percentage points.
Fortrea’s third quarter results were met with a significant positive response from the market, as robust demand across its clinical pharmacology and clinical development businesses drove revenue growth. Management highlighted that win rates with biotech clients doubled compared to the prior quarter, and strong RFP volumes led to new business wins in both new and repeat clients. CEO Anshul Thakral credited operational improvements, noting, “Our win rates improved significantly, reaching the highest level in six quarters,” and emphasized the company’s ability to accelerate site selection and trial enrollment through technology and workflow enhancements.
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Fortrea (NASDAQ:FTRE) and the rest of the drug development inputs & services stocks fared in Q3.
A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns.
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Fortrea Holdings, Inc. (NasdaqGS: FTRE).
Clinical research company Fortrea Holdings (NASDAQ:FTRE) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 3.9% year on year to $701.3 million. The company’s full-year revenue guidance of $2.73 billion at the midpoint came in 3.1% above analysts’ estimates. Its non-GAAP profit of $0.12 per share was 22.8% below analysts’ consensus estimates.
Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE)
jumped 25.3% in the morning session after the company reported third-quarter financial results that showed stronger-than-expected revenue and an improved outlook for the full year. For the third quarter, Fortrea announced revenues of $701.3 million, which surpassed analyst estimates. However, its adjusted earnings of $0.12 per share fell short of projections. Despite the mixed bottom-line results, investors appeared to focus on the company's future prospects. Fortrea raised its revenue guidance for the full year to a midpoint of $2.73 billion, up from its previous forecast of $2.65 billion. This improved outlook, along with the strong quarterly sales, signaled confidence in the company's growth, outweighing the earnings miss.
In a financial landscape often dictated by strict adherence to earnings forecasts, recent market movements have showcased a fascinating deviation from traditional expectations. Public companies like Fortrea Holdings (NASDAQ: FTRE) and Flowco Holdings (NYSE: FLOC) have seen their stock prices surge, even in the face of missed earnings per share
Clinical research company Fortrea Holdings (NASDAQ:FTRE) announced better-than-expected revenue in Q3 CY2025, with sales up 3.9% year on year to $701.3 million. The company’s full-year revenue guidance of $2.73 billion at the midpoint came in 3.1% above analysts’ estimates. Its non-GAAP profit of $0.12 per share was 25.7% below analysts’ consensus estimates.
Fortrea posts Q3 2025 results with a revenue beat but an adjusted EPS miss. The CRO raises its full-year revenue guidance and reports a strong book-to-bill ratio of 1.13x.
